ARTICLE | Company News
Bionure Farma, Spiral Therapeutics deal
March 31, 2017 7:33 PM UTC
Bionure granted Spiral an option to acquire exclusive, worldwide rights to Bionure’s preclinical serum/glucocorticoid regulated kinase 2 (SGK2) agonists BN201 and BN119 to treat otolaryngology indications. Spiral plans to exercise the option by 3Q17. If exercised, Bionure will be eligible to receive up to $4.9 million in milestones, plus royalties...
BCIQ Target Profiles